When referring patients for genetics counseling and possible testing for hereditary risk, oncology nurses can help relieve their trepidation and anxiety by explaining what to expect during the visit. See the sidebar for key indications for referral.

Get to know Anne M. Ireland, MSN, RN, AOCN^®, CENP, director-at-large on the ONS Board of Directors from 2018–2021. Anne is the executive director for community nursing practice at the City of Hope National Medical Center in Duarte, CA.

Combining a traditional 12-point biopsy with magnetic resonance imaging (MRI) improves the accuracy of prostate cancer diagnosis, according to findings from a new National Institutes of Health (NIH) study published in the New England Journal of Medicine. 

We are oncology nurses. We don’t shy away from hard discussions. We have the skills and tools to help others. But this pandemic is different. The COVID-19 coronavirus has changed the rules. It’s ushered in social distancing, limited contact, and induced a new level of panic. COVID-19 doesn’t care if you are a nurse or a patient. It is an equalizer between us all. 

On March 18, 2020, the U.S. Food and Drug Administration (FDA) issued a guidance for industry, investigators, and institutional review boards conducting clinical trials during the COVID-19 coronavirus pandemic in recognition that it may affect the conduct of clinical trials of medical products, including drugs, devices, and biologic products.

Adding atezolizumab to treatment with bevacizumab, carboplatin, and paclitaxel as first-line therapy for metastatic, nonsquamous non-small cell lung cancer (NSCLC) is associated with survival benefit—but it comes at a cost, researchers said in study results published in JAMA Network Open. In comparison, pembrolizumab offers a more cost-effective survival benefit. 

Change at the federal level takes time and perseverance. Thanks to great effort from the smoking cessation community—including ONS—the federal government is updating package and advertising warning for tobacco products for the first time since 1984. Advocates have been calling on agencies to exercise authority over tobacco products along with their marketing and distribution, and on March 17, 2020, the U.S. Food and Drug Administration (FDA) issued a final rule requiring new health warning labels for cigarette packages and advertisements.

To address the COVID-19 coronavirus pandemic, on March 22, 2020, the U.S. Food and Drug Administration (FDA) issued a new guidance to sponsors and healthcare providers regarding certain Risk Evaluation and Mitigation Strategy (REMS)-required testing during this time.

The alarmingly quick spread of the COVID-19 coronavirus has put a strain on the U.S. healthcare system, including the availability of personal protective equipment and other safety resources. The speed at which the virus spreads requires an even swifter response from federal agencies, government officials, and public health experts to combat the disease.

On March 22, 2020, the U.S. Food and Drug Administration took action to increase the availability of ventilators, accessories, and other respiratory devices during the COVID-19 coronavirus pandemic to support patients with respiratory failure or difficulty breathing.